353 related articles for article (PubMed ID: 17454707)
1. An association of CYP2A6 genotype and smoking topography.
Strasser AA; Malaiyandi V; Hoffmann E; Tyndale RF; Lerman C
Nicotine Tob Res; 2007 Apr; 9(4):511-8. PubMed ID: 17454707
[TBL] [Abstract][Full Text] [Related]
2. Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy.
Malaiyandi V; Lerman C; Benowitz NL; Jepson C; Patterson F; Tyndale RF
Mol Psychiatry; 2006 Apr; 11(4):400-9. PubMed ID: 16402128
[TBL] [Abstract][Full Text] [Related]
3. The effect of methoxsalen on nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism in vivo.
Sellers EM; Ramamoorthy Y; Zeman MV; Djordjevic MV; Tyndale RF
Nicotine Tob Res; 2003 Dec; 5(6):891-9. PubMed ID: 14668073
[TBL] [Abstract][Full Text] [Related]
4. Genetic variation in CYP2A6-mediated nicotine metabolism alters smoking behavior.
Tyndale RF; Sellers EM
Ther Drug Monit; 2002 Feb; 24(1):163-71. PubMed ID: 11805739
[TBL] [Abstract][Full Text] [Related]
5. Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk.
Tyndale RF; Sellers EM
Drug Metab Dispos; 2001 Apr; 29(4 Pt 2):548-52. PubMed ID: 11259349
[TBL] [Abstract][Full Text] [Related]
6. CYP2A6 genetic polymorphisms and biomarkers of tobacco smoke constituents in relation to risk of lung cancer in the Singapore Chinese Health Study.
Yuan JM; Nelson HH; Carmella SG; Wang R; Kuriger-Laber J; Jin A; Adams-Haduch J; Hecht SS; Koh WP; Murphy SE
Carcinogenesis; 2017 Apr; 38(4):411-418. PubMed ID: 28182203
[TBL] [Abstract][Full Text] [Related]
7. CYP2A6 genotype, phenotype, and the use of nicotine metabolites as biomarkers during ad libitum smoking.
Malaiyandi V; Goodz SD; Sellers EM; Tyndale RF
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1812-9. PubMed ID: 17035386
[TBL] [Abstract][Full Text] [Related]
8. The role of CYP2A6 in the emergence of nicotine dependence in adolescents.
Audrain-McGovern J; Al Koudsi N; Rodriguez D; Wileyto EP; Shields PG; Tyndale RF
Pediatrics; 2007 Jan; 119(1):e264-74. PubMed ID: 17130279
[TBL] [Abstract][Full Text] [Related]
9. CYP2A6 polymorphisms are associated with nicotine dependence and influence withdrawal symptoms in smoking cessation.
Kubota T; Nakajima-Taniguchi C; Fukuda T; Funamoto M; Maeda M; Tange E; Ueki R; Kawashima K; Hara H; Fujio Y; Azuma J
Pharmacogenomics J; 2006; 6(2):115-9. PubMed ID: 16402086
[TBL] [Abstract][Full Text] [Related]
10. A meta-analytic review of the CYP2A6 genotype and smoking behavior.
Carter B; Long T; Cinciripini P
Nicotine Tob Res; 2004 Apr; 6(2):221-7. PubMed ID: 15203795
[TBL] [Abstract][Full Text] [Related]
11. Nicotine metabolite ratio predicts smoking topography and carcinogen biomarker level.
Strasser AA; Benowitz NL; Pinto AG; Tang KZ; Hecht SS; Carmella SG; Tyndale RF; Lerman CE
Cancer Epidemiol Biomarkers Prev; 2011 Feb; 20(2):234-8. PubMed ID: 21212060
[TBL] [Abstract][Full Text] [Related]
12. Genetic variation in CYP2A6 predicts neural reactivity to smoking cues as measured using fMRI.
Tang DW; Hello B; Mroziewicz M; Fellows LK; Tyndale RF; Dagher A
Neuroimage; 2012 May; 60(4):2136-43. PubMed ID: 22342802
[TBL] [Abstract][Full Text] [Related]
13. Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence.
Malaiyandi V; Sellers EM; Tyndale RF
Clin Pharmacol Ther; 2005 Mar; 77(3):145-58. PubMed ID: 15735609
[TBL] [Abstract][Full Text] [Related]
14. Genetically decreased CYP2A6 and the risk of tobacco dependence: a prospective study of novice smokers.
O'Loughlin J; Paradis G; Kim W; DiFranza J; Meshefedjian G; McMillan-Davey E; Wong S; Hanley J; Tyndale RF
Tob Control; 2004 Dec; 13(4):422-8. PubMed ID: 15564629
[TBL] [Abstract][Full Text] [Related]
15. Determinants of the rate of nicotine metabolism and effects on smoking behavior.
Johnstone E; Benowitz N; Cargill A; Jacob R; Hinks L; Day I; Murphy M; Walton R
Clin Pharmacol Ther; 2006 Oct; 80(4):319-30. PubMed ID: 17015050
[TBL] [Abstract][Full Text] [Related]
16. Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking.
Rao Y; Hoffmann E; Zia M; Bodin L; Zeman M; Sellers EM; Tyndale RF
Mol Pharmacol; 2000 Oct; 58(4):747-55. PubMed ID: 10999944
[TBL] [Abstract][Full Text] [Related]
17. Smoking behavior and related cancers: the role of CYP2A6 polymorphisms.
Nakajima M
Curr Opin Mol Ther; 2007 Dec; 9(6):538-44. PubMed ID: 18041664
[TBL] [Abstract][Full Text] [Related]
18. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians.
Schoedel KA; Hoffmann EB; Rao Y; Sellers EM; Tyndale RF
Pharmacogenetics; 2004 Sep; 14(9):615-26. PubMed ID: 15475735
[TBL] [Abstract][Full Text] [Related]
19. Effects of cigarette smoking and exposure to cadmium and lead on phenotypic variability of hepatic CYP2A6 and renal function biomarkers in men.
Satarug S; Ujjin P; Vanavanitkun Y; Nishijo M; Baker JR; Moore MR
Toxicology; 2004 Nov; 204(2-3):161-73. PubMed ID: 15388242
[TBL] [Abstract][Full Text] [Related]
20. Genetic determinants of cytochrome P450 2A6 activity and biomarkers of tobacco smoke exposure in relation to risk of lung cancer development in the Shanghai cohort study.
Yuan JM; Nelson HH; Butler LM; Carmella SG; Wang R; Kuriger-Laber JK; Adams-Haduch J; Hecht SS; Gao YT; Murphy SE
Int J Cancer; 2016 May; 138(9):2161-71. PubMed ID: 26662855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
